JPMorgan Chase & Co. Increases ANI Pharmaceuticals (NASDAQ:ANIP) Price Target to $115.00

ANI Pharmaceuticals (NASDAQ:ANIP – Free Report) had its price objective raised by JPMorgan Chase & Co. from $95.00 to $115.00 in a research note published on Wednesday,Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the specialty pharmaceutical company’s stock. A number of other equities analysts also recently weighed in on the […]

Leave a Reply

Your email address will not be published.

Previous post Citizens Jmp Initiates Coverage on Assembly Biosciences (NASDAQ:ASMB)
Next post Tesla’s (TSLA) Sell Rating Reiterated at UBS Group